Back to results
US 2021/0231674 A1Published application
Treatment of spontaneous preterm birth
AssigneeNx Prenatal Inc.
InventorsAlan M. EZRIN, Brian D. BROHMAN
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to biomarkers of preterm birth, biomarkers of term birth, and methods of use thereof. In particular, the present disclosure provides methods of determining whether a pregnant woman is at an increased risk for premature delivery. The present disclosure further provides methods for decreasing a pregnant woman's risk for premature delivery.
Claims8
1-22. (canceled)
A method of detecting the protein levels of a plurality of microparticle-associated proteins associated with spontaneous preterm birth, the method comprising:
- (a) obtaining a blood sample from a pregnant subject;
- (b) isolating microparticles are from the blood using size-exclusion chromatography with an agarose solid phase and non-buffered aqueous liquid phase;
- and
- (c) detecting the protein levels of Inter-alpha trypsin inhibitor H4 (ITIH4), Transferrin (TF), and Plasma protease C1 inhibitor (SERPING1) in the microparticles using liquid chromatography/mass spectrometry (LC/MS).
1 more element
Dependencies are inferred from the claim text.